The Annals
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


Drug Intelligence & Clinical Pharmacy: Vol. 18, No. 6, pp. 462-465.
© 1984 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Birkhimer, L.
Right arrow Articles by DeVane, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Birkhimer, L.
Right arrow Articles by DeVane, C.


Research Articles

The neuroleptic malignant syndrome: presentation and treatment

LJ Birkhimer and CL DeVane

The neuroleptic malignant syndrome is a potentially lethal reaction following the use of antipsychotic medications. The four cardinal signs are hyperthermia, muscular rigidity, autonomic dysfunction, and altered consciousness. The differential diagnosis of the syndrome includes malignant hyperthermia of anesthesia, heat stroke, and acute lethal catatonia. Treatment consists of prompt recognition of the syndrome and initiation of intense supportive measures to manage the hyperthermia and prevent secondary complications. Clinical reports describing beneficial results from use of anticholinergic agents, amantadine, bromocriptine, and dantrolene are reviewed.





homecopy help contact us subscription past issues search current issue
Copyright © 1984 by Harvey Whitney Books Company.